Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KLIMT: Dapagliflozin/Sitagliptin FDC vs Pioglitazone/Sitagliptin in T2DM
NCT06875193Phase 4Recruiting
- Sponsor
- Dongwha Pharmaceutical Co., Ltd.
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dongwha Pharmaceutical Co., Ltd. Primary endpoint: Variance in HbA1c from baseline to 24 weeks. Started May 2024; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06875193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06875193.